Clinical Trials Directory

Trials / Completed

CompletedNCT04477096

Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine

Study on the Drug Interaction of HS-10234 and Emtricitabine in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The study is being conducted to evaluate drug interaction between HS-10234 and Emtricitabine after multiple dose in healthy subjects.

Detailed description

The study includes two parts. Part 1 is to evaluate the impact of Emtricitabine on HS-10234. Part 2 is to evaluate the impact of HS-10234 on Emtricitabine.

Conditions

Interventions

TypeNameDescription
DRUGHS-10234HS-10234
DRUGEmtricitabineEmtricitabine

Timeline

Start date
2020-08-03
Primary completion
2020-09-24
Completion
2020-09-24
First posted
2020-07-20
Last updated
2020-10-01

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04477096. Inclusion in this directory is not an endorsement.

Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine (NCT04477096) · Clinical Trials Directory